Simple. Fast. Protection.

Over 35,000 catheter days without bacterial infections^1-10

Conclusions from recent clinical studies show no occurrence of bloodstream infections associated with use of the POWERWAND^™ catheters. These studies combined have a total of 35,000 catheter days without bacterial infections.^2-11

Insertion

Offering intuitive and easy insertion methods, the POWERWAND^™ midline catheters help reduce the number of steps needed to insert the catheter compared to standard modified seldinger techniques.

Performance

Once in place, the POWERWAND^™ midline catheters are designed to last up to 29 days and provide full completion of IV therapy. Evidence demonstrates the POWERWAND^™ catheters reduces major complications associate with vascular access devices and, thus, helps patients experience the increased satisfaction of a one-stick hospitalization.^2-11

What makes the POWERWAND^™ different?

ECHOGENIC

Once in the vein, the echogenic properties of the POWERWAND^™ catheter allow for ultrasound visualization

Images: Longitudinal and Transverse

BLOOD DRAWABILITY

Studies show 60-90% blood drawability for full length of stay^7,8,10

THERMOFORMED TIP

Thermoformed tip in order to avoid jagged edges

Images: Trimmed catheter and POWERWAND™ catheter

POWER INJECTION

High power injection rating: 8 mL/sec, 325 psi

THROMBORESISTANT¹

The POWERWAND^™ catheter is shown in vivo to resist thrombus formation with respect to thrombus on the surface of the catheter and thrombus on the wall of the vein, as compared with a commonly used control device.¹

Images: Control device and POWERWAND^™ catheter

HIGH FLOW

High flow rates: 75-180 mL/min

KINK RESISTANT

The unique material of the POWERWAND^™ catheter is designed to be kink resistant to provide reliability during both insertion and dwell times.

Images: Standard catheter and POWERWAND^™ catheter

POWERWAND^™ Kits and Accessories

Quick Kit

Needle Guides w/ probe cover

Dressing Change Kits

“As of this writing, it [POWERWAND^™] remains the only device within our organization that has never been associated with a bloodstream infection beyond 1 year.”

DeVries M, Lee J. Infection free midline catheter implementation at a community hospital (2 years). American Journal of Infection Control 2019, https://doi.org/10.1016/j.ajic.2019.03.001.
M.D. were paid consultants with Access Scientific

"In our study, by replacing central lines with midlines in patients, we essentially decreased risk factors such as dressing changes, catheter care, and duration of central line use.”

Pathak R. MD, Patel A. MD, Enuh H. MD, Adekunle O. MD, Shrisgantharajah V. MD, and Diaz K. MD. The Incidence of Central Line–Associated Bacteremia After the Introduction of Midline Catheters in a Ventilator Unit Population. Infectious Disease in Clinical Practice 2015; 23: 131-134.

1. FDA cleared 510(k) POWERWAND has shown in vivo to be thromboresistant with respect to both thrombus on the surface of the catheter and thrombus on the wall of the vein, based upon 72-hour canine jugular vein thromboresistance studies, This pre-clinical in vivo evaluation does not necessarily predict clinical performance with respect to thrombus formation

2. Warrington WG, Penoyer DA, Kamps T, et al. Outcomes of Using a Modified Seldinger Technique for Long Term Intravenous Therapy in Hospitalized Patients with Difficult Venous Access.
JAVA 2012; (17)1;24-31.

3. *Moureau N, Sigl G, Hill M. How to Establish an Effective Midline Program: A Case Study of 2 Hospitals. JAVA 2015; 20(3):179-188

4. Caparas JV, Hung HS. Vancomycin Administration Through a Novel Midline Catheter: Summary of a 5-Year, 1086-Patient Experience in an Urban Community Hospital. J Vasc Access 2017;22(1):38-41.

5. *DeVries M, Lee J. Infection free midline catheter implementation at a community hospital (2 years). American Journal of Infection Control 2019, https://doi.org/10.1016/j.ajic.2019.03.001.

6. Seo, H., Altshuler, D., Dubrovskaya, Y., et al (2020). The Safety of Midline Catheters for Intravenous Therapy at a Large Academic Medical Center. Annals of Pharmacotherapy, 54(3), 232–238. https://doi.org/10.1177/1060028019878794

7. Castro S, Allison R. Use of a Midline (Extended Dwell Catheter) Device Improves Patient Safety and Saves Costs Compared to PICCs. Poster presented at 2012 Association for Vascular Access Annual Scientific Meeting.

8. Bird D. The Power of Choice: Midline Catheter Improves Patient Safety and Comfort While Increasing Vascular Access Revenue and Productivity. Poster presented at 2012 Association for Vascular Access Annual Scientific Meeting.

9. Caparas J. Staff Education/Training Aids Implementation of Advanced Midline Catheter. Poster presented at 2013 Infusion Nurses Society Annual Convention and Industrial Exhibition.

10. Baliad P, Peterson S. Midline Catheter Reduced Infiltrations for Coronary Artery Bypass Graft Patients. Poster presented at 2013 Infusion Nurses Society Annual Convention and Industrial Exhibition.

11. Robbins JR, Phillips SA, Vanfosson CA. Implementation of a Midline Catheter for Burn Patients to Decrease Frequent Peripheral Sticks and Infection Risk. Poster presented at American Burn Association Annual Meeting, March 25-28, 2014, Boston, MA.

*M.D. and N.M. were paid consultants for Access Scientific, LLC. Smiths Medical acquired substantially all of the assets of Access Scientific, LLC, including the POWERWAND™ products, on May 13, 2020.

POWERWAND^™ Midline Catheters

Simple. Fast. Protection.